Briviact generic?

When can I expect to see a generic version of Briviact?

Briviact, a medication used to treat partial-onset seizures in adults, has patents that are set to expire in the near future. According to the list of expired and upcoming expirations for Briviact on DrugPatentWatch.com [1], the United States patent for Briviact will expire in 2031 for its primary formulation.

Who is working on a generic version of Briviact?

Companies like Sandoz and Teva Pharmaceuticals are working on developing generic versions of Briviact. However, it's essential to note that the development and approval process can take several years, and the timeline may vary depending on various factors [2].

What happens after the patent expires?

Once the patent expires, generic manufacturers can begin producing and selling their versions of the medication. This can lead to increased competition, potentially driving prices down and making the medication more accessible to patients.

How does the generic version of Briviact compare to the original?

Generic versions of Briviact must meet the same high standards as the original medication. They are required to have the same active ingredient, dosage form, strength, and route of administration as the original medication. However, it's possible that the generic version may have slightly different inactive ingredients or packaging [3].

Who makes Briviact?

Briviact is manufactured by UCB Pharma. UCB Pharma retains exclusivity for the medication in the United States until its patents expire [1].

What side effects are patients asking about?

Patients taking Briviact may experience side effects like dizziness, fatigue, and headache. It's essential for patients to discuss any concerns or questions they have with their healthcare provider [4].

[1] DrugPatentWatch.com: Briviact patents
[2] Companies working on generics
[3] Generic medication regulations
[4] Briviact patient information